Heartflow to Report Second Quarter 2026 Financial Results on August 13, 2026

Rhea-AI Summary

Heartflow (Nasdaq: HTFL) will release its second quarter 2026 financial results after market close on Thursday, August 13, 2026. Management will hold a conference call at 1:30 p.m. PT / 4:30 p.m. ET the same day, with access via online registration to receive dial-in details and a unique PIN.

A live and archived webcast will be available in the Investor Relations section of Heartflow’s website, with the replay accessible for 12 months. Heartflow highlights its AI-based coronary artery disease solutions, built on more than 200 million annotated CTA images, adoption at over 1,800 institutions, and clinical evidence from over 625 peer-reviewed publications and 200 studies covering more than 365,000 patients.

News Market Reaction – HTFL

-1.99%

-1.99% Session close to close

In the Jul 24 session, HTFL declined 1.99%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

Insider context recorded Net Selling over 90 days, with 2,125,024 shares sold and 0 bought. That pla...

Analysis

Insider context recorded Net Selling over 90 days, with 2,125,024 shares sold and 0 bought. That platform record adds a governance-risk lens to the scheduled report; low short positioning was also reported.

Key Figures

Results release date: August 13, 2026 Conference call time: 1:30 p.m. PT / 4:30 p.m. ET Webcast archive: 12 months +5 more

8 metrics

Results release date August 13, 2026 Second quarter 2026 financial results

Conference call time 1:30 p.m. PT / 4:30 p.m. ET August 13, 2026

Webcast archive 12 months Following completion of the live call

Institution adoption More than 1,800 institutions Global adoption

Peer-reviewed publications More than 625 publications Clinical and research support

Annotated CTA images More than 200 million Data foundation for AI models

Patients assessed Over 365,000 patients Clinical evidence across over 200 studies

Image acceptance rate Exceed 97% Heartflow coronary CTA images

Previous Earnings date Reports

2 past events · Latest: Apr 23 (Neutral)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 23	Q1 earnings date	Neutral	-2.6%	Announced the Q1 2026 results release date and accompanying conference call.
Feb 13	FY2025 earnings date	Neutral	+7.8%	Scheduled fourth-quarter and full-year 2025 financial results and investor conference call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Tag-specific earnings-date notices produced mixed 24-hour reactions, with one negative move and one positive move.

Key Terms

coronary artery disease, coronary CTA, HITRUST, SOC 2 Type 2, +2 more

6 terms

coronary artery disease medical

"AI technology for coronary artery disease (CAD)"

Coronary artery disease is a condition in which the blood vessels that supply the heart become narrowed or blocked by fatty buildup, reducing oxygen-rich blood flow and making the heart work harder. For investors, it matters because the condition drives demand for medications, medical devices, diagnostics and procedures, can affect healthcare spending and payer policies, and influences the financial prospects of companies involved in cardiovascular care—similar to how a clogged pipe changes maintenance and replacement needs.

coronary CTA medical

"Heartflow’s coronary CTA image acceptance rates exceed 97%"

Coronary CTA is a noninvasive CT scan that produces detailed pictures of the heart’s blood vessels to check for blockages or narrowing. Think of it as a high-resolution road map for a car engine’s plumbing; it shows where flow might be restricted so doctors can decide whether treatment is needed. Investors watch its use and reimbursement because wider clinical adoption drives demand for scanners, software, and related diagnostic services.

HITRUST regulatory

"including HITRUST, SOC 2 Type 2, ISO 13485, and ISO 27001"

HITRUST is an independent organization and a widely used security and privacy framework that helps healthcare and related companies show they protect sensitive data like patient records. Think of it as a standardized lock-and-inspection checklist auditors use to confirm an organization follows strong data security and regulatory rules. For investors, HITRUST recognition reduces the risk of costly data breaches, regulatory fines, and reputational damage, making a business a safer long-term bet.

SOC 2 Type 2 regulatory

"including HITRUST, SOC 2 Type 2, ISO 13485, and ISO 27001"

SOC 2 Type 2 is an independent audit that verifies a service provider’s operational controls for security, availability, processing integrity, confidentiality and privacy over a sustained period. Think of it as a multi-week inspection that checks not just that security measures exist but that they actually work day to day; for investors, a clean SOC 2 Type 2 report lowers the risk of data breaches, downtime and regulatory problems and signals stronger operational reliability.

ISO 13485 regulatory

"including HITRUST, SOC 2 Type 2, ISO 13485, and ISO 27001"

ISO 13485 is an international quality management standard for organizations that design, produce, or service medical devices. Think of it as a factory’s rulebook and checklist that helps ensure products are safe, consistently made, and meet regulatory rules worldwide. For investors, certification signals lower operational and regulatory risk, easier market access, and greater reliability of a company’s medical products and supply chain — similar to buying from a trusted, inspected supplier.

ISO 27001 regulatory

"including HITRUST, SOC 2 Type 2, ISO 13485, and ISO 27001"

ISO 27001 is an internationally recognized standard that sets out the best practices for managing and protecting sensitive information within an organization. It acts like a security blueprint, helping companies ensure data is kept safe from theft, loss, or damage. For investors, organizations with ISO 27001 certification demonstrate a strong commitment to information security, reducing the risk of data breaches that could impact business stability and reputation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, July 23, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the second quarter of 2026 after market close on Thursday, August 13, 2026. Management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on August 13, 2026.

Those interested in listening to the conference call should register online using this link. Once registered, participants will receive dial-in numbers and a unique PIN to join the call. Participants are encouraged to register more than 15 minutes prior to the start of the call. A live and archived webcast of the event will also be available on the “Investor Relations” section of the Heartflow website at https://ir.heartflow.com. The archived version will be available for 12 months following completion of the live call.

About Heartflow’s Technology and Research

Heartflow’s technology is redefining precision cardiovascular care through clinically-proven AI and the world’s largest coronary imaging dataset. Heartflow has been adopted by more than 1,800 institutions globally and continues to strengthen its commercial presence to make this cutting-edge solution more widely available to an increasingly diverse patient population. Backed by American College of Cardiology and American Heart Association (ACC/AHA) guidelines and supported by more than 625 peer-reviewed publications, Heartflow has redefined how clinicians manage care for over 650,000 patients worldwide.¹ Key benefits include:

• Unmatched Proprietary data pipeline: Built from the world’s largest database of more than 200 million annotated CTA images, Heartflow’s data foundation powers advanced AI models that deliver highly accurate, reproducible insights across diverse patient populations.
• Extensive clinical and real-world validation: Heartflow’s AI-driven solutions have been validated through clinical evidence in over 200 studies assessing over 365,000 patients. Heartflow is the only AI platform prospectively validated against invasive gold standards and demonstrated through real-world evidence to improve patient outcomes.^2,3,4,5 Proven in real-world practice with reproducibility and accuracy, Heartflow’s coronary CTA image acceptance rates exceed 97%.
• Seamless clinical integration via upgraded workflow: Heartflow delivers final quality-reviewed analyses instantly upon order, enabling clinicians to move from diagnosis to decision without delay.
• Quality system, global security and patient-data integrity compliance: Heartflow meets or exceeds leading international standards, including HITRUST, SOC 2 Type 2, ISO 13485, and ISO 27001.

About Heartflow, Inc.

Heartflow is transforming coronary artery disease from the world’s leading cause of death into a condition that can be detected early, diagnosed accurately, and managed for life. The Heartflow One platform uses AI to turn coronary CTA images into personalized 3D models of the heart, providing clinically meaningful, actionable insights into plaque location, volume, and composition and its effect on blood flow — all without invasive procedures. Discover how we’re shaping the future of cardiovascular care at heartflow.com

Investor Contact
Nick Laudico
nlaudico@heartflow.com

Media Contact
Elliot Levy
elevy@heartflow.com

____________________________
¹ Gulati, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation & Diagnosis of Chest Pain. J Am Coll Cardiol
² Narula, et al. E HJ CVI 2024
³ Danad, et al. JAMA Cardiol 2017
⁴ Fairbairn et al. Coronary CT Angiography Plaque as a Predictor of Death, Cardiovascular Death and Myocardial Infarction. Presented at AHA 2025. (Real-world study with n=7,899 patients, higher TPV results in increased cardiovascular death and MI)
⁵ Madsen KT, et al. ADVANCE-DK 7-year. Presented at TCT Scientific Sessions 2024 (n=900 patients determined a 2.5x increase in cardiovascular events or deaths at 7 years)

FAQ

When will Heartflow (NASDAQ: HTFL) report its Q2 2026 financial results?

Heartflow will report its Q2 2026 financial results on August 13, 2026 after market close. According to Heartflow, the release will be followed by a management conference call that same afternoon to discuss the quarterly financial performance and related updates.

What time is the Heartflow (HTFL) Q2 2026 earnings conference call on August 13, 2026?

The Heartflow Q2 2026 earnings conference call starts at 1:30 p.m. PT / 4:30 p.m. ET on August 13, 2026. According to Heartflow, investors must register online to receive dial-in details and a unique PIN to join the live discussion.

How can investors access the Heartflow (HTFL) Q2 2026 earnings webcast and replay?

Investors can access the Heartflow Q2 2026 earnings webcast through the Investor Relations section of the company’s website. According to Heartflow, a live stream and archived replay will be available, with the archive accessible for 12 months after the call.

Do investors need to register in advance for the Heartflow (HTFL) Q2 2026 earnings call?

Yes, investors must register online in advance to join the Heartflow Q2 2026 earnings call. According to Heartflow, registration provides dial-in numbers and a unique PIN, and participants are encouraged to register more than 15 minutes before the call begins.

What technology does Heartflow (HTFL) highlight alongside its Q2 2026 earnings date announcement?

Heartflow highlights its AI-driven coronary artery disease platform built on over 200 million annotated CTA images. According to Heartflow, its technology is supported by more than 625 peer-reviewed publications, over 200 studies, and adoption by over 1,800 institutions worldwide.

How extensive is the clinical validation of Heartflow’s AI technology mentioned in the HTFL Q2 2026 update?

Heartflow reports clinical validation through over 200 studies involving more than 365,000 patients. According to Heartflow, its AI platform is prospectively validated against invasive gold standards and has been used to help manage care for over 650,000 patients globally.